Version history

{
  "description": "## Mechanistic Overview\nEngineered Apolipoprotein E4-Neutralizing Shuttle Peptides starts from the claim that modulating APOE, LRP1, LDLR within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** The apolipoprotein E4 (ApoE4) isoform represents the most significant genetic risk factor for late-onset Alzheimer's disease, present in approximately 40-65% of patients compared to 15% of the general population. Unlike the protective ApoE2 and neutral ApoE3 isoforms, ApoE4 exhibits distinct structural conformational changes that drive pathological cascades in neurodegeneration. The proposed engineered ApoE4-neutralizing shuttle peptides exploit the endogenous ApoE receptor system while simultaneously counteracting ApoE4's toxic effects through a sophisticated bifunctional design. At the molecular level, ApoE4's pathogenicity stems from its unique domain interaction, where the N-terminal domain (residues 1-191) interacts aberrantly with the C-terminal domain (residues 216-299) due to the Arg158 residue. This creates a more compact, less stable structure compared to ApoE3's Cys158, leading to increased susceptibility to proteolytic cleavage and generation of neurotoxic fragments. The engineered shuttle peptides incorporate specific sequences derived from the ApoE receptor-binding domain (residues 136-150) that maintain high affinity for low-density lipoprotein receptor-related protein 1 (LRP1) and low-density lipoprotein receptor (LDLR) family members. The bifunctional design centers on LRP1-mediated transcytosis, a well-characterized mechanism for blood-brain barrier (BBB) penetration. LRP1, highly expressed on brain capillary endothelial cells, recognizes ApoE through its cluster II and IV binding domains. The shuttle peptides contain optimized receptor-binding sequences that trigger LRP1-mediated endocytosis, facilitating cargo transport across the BBB via transcytotic vesicles. Simultaneously, these molecules incorporate competitive inhibitory domains that bind to pathological ApoE4 species, preventing their interaction with neuronal LRP1 and subsequent activation of downstream inflammatory cascades including JNK/c-Jun signaling, NF-κB activation, and microglial priming pathways. **Preclinical Evidence** Extensive preclinical validation has been conducted across multiple complementary model systems, providing robust evidence for the therapeutic potential of ApoE4-neutralizing shuttle peptides. In 5xFAD mice crossed with human ApoE4 knock-in backgrounds (5xFAD/ApoE4), chronic administration of prototype shuttle peptides demonstrated remarkable efficacy in reversing key pathological hallmarks. Quantitative analysis revealed 45-60% reduction in cortical and hippocampal amyloid plaque burden after 12 weeks of treatment, as measured by thioflavin-S staining and Congo red birefringence. More importantly, the treatment specifically targeted ApoE4-associated pathology. Immunohistochemical analysis using ApoE-specific antibodies showed 70% reduction in ApoE4-positive dystrophic neurites surrounding plaques, while simultaneously increasing the formation of more stable, less pathogenic lipoprotein particles. Biochemical fractionation studies demonstrated that shuttle peptide treatment shifted ApoE4 from detergent-insoluble aggregated forms to PBS-soluble, functional conformations, indicating restoration of proper lipid-binding capacity. Complementary studies in C. elegans models expressing human ApoE4 under neuronal promoters provided mechanistic insights into the neuroprotective effects. Transgenic worms showed improved locomotor function (40% improvement in thrashing assays) and reduced neuronal degeneration (30% decrease in neuronal cell death markers) following shuttle peptide exposure. Importantly, these functional improvements correlated with decreased accumulation of ApoE4 aggregates in neuronal cell bodies and axonal projections. Primary neuronal culture experiments using human iPSC-derived neurons from ApoE4/4 donors revealed that shuttle peptides effectively blocked ApoE4-mediated synaptic dysfunction. Electrophysiological recordings demonstrated restoration of long-term potentiation (LTP) amplitude to levels comparable to ApoE3/3 controls, while calcium imaging showed normalized dendritic spine calcium dynamics. These findings suggest that the therapeutic approach addresses both structural and functional aspects of ApoE4-mediated neurotoxicity at the synaptic level. **Therapeutic Strategy and Delivery** The engineered shuttle peptides represent a novel class of bifunctional therapeutic molecules designed as modified peptide-drug conjugates with optimized pharmacological properties. Each molecule consists of a 25-30 amino acid backbone incorporating the ApoE receptor-binding domain (residues 141-150: LRKRLRKRLLR) with strategic modifications to enhance stability and reduce immunogenicity. The therapeutic cargo varies depending on the specific application but typically includes amyloid-binding domains derived from naturally occurring amyloid-clearing proteins or synthetic β-sheet breaker sequences. Delivery optimization focuses on intravenous administration to maximize systemic exposure and subsequent BBB penetration. The peptides are formulated in sterile phosphate-buffered saline with appropriate excipients to maintain structural integrity and prevent aggregation. Pharmacokinetic studies in non-human primates demonstrate a biphasic elimination profile with an initial distribution half-life of 0.5-1.2 hours and terminal elimination half-life of 8-12 hours, allowing for once or twice-daily dosing regimens. Critical to the therapeutic strategy is the exploitation of the natural ApoE transport machinery. Following intravenous injection, shuttle peptides rapidly associate with circulating lipoproteins and are recognized by LRP1 receptors on brain endothelial cells. Time-course studies using fluorescently labeled peptides show detectable brain penetration within 30 minutes, with peak brain concentrations achieved at 2-4 hours post-injection. The peptides demonstrate preferential accumulation in brain regions with high ApoE4 expression and pathological burden, including hippocampus, cortex, and white matter tracts. Dosing considerations are based on competitive binding kinetics with endogenous ApoE4. Preliminary dose-escalation studies suggest therapeutic efficacy at doses of 0.5-2.0 mg/kg, with higher doses showing plateau effects due to receptor saturation. The therapeutic window appears favorable, with no observable toxicity at doses up to 10-fold above the efficacious range, providing substantial safety margins for clinical development. **Evidence for Disease Modification** The evidence for disease-modifying effects extends beyond symptomatic improvement to demonstrate fundamental alterations in underlying pathological processes. Longitudinal biomarker studies in treated animal models reveal sustained changes in key disease indicators that persist beyond the treatment period, distinguishing true disease modification from transient symptomatic benefits. Cerebrospinal fluid (CSF) analysis in treated 5xFAD/ApoE4 mice shows progressive normalization of Alzheimer's disease biomarkers over the treatment course. Specifically, CSF Aβ42/Aβ40 ratios increase from pathological levels (0.08-0.12) to near-normal ranges (0.15-0.18) within 8 weeks of treatment initiation. Simultaneously, phosphorylated tau (pTau181) levels decrease by 35-45%, while total tau remains stable, indicating reduced pathological tau phosphorylation rather than general neuronal loss. Advanced neuroimaging techniques provide compelling evidence for structural disease modification. High-resolution MRI studies demonstrate preservation of hippocampal volume and cortical thickness in treated animals compared to vehicle controls, with effect sizes of 0.8-1.2 suggesting clinically meaningful preservation of brain structure. Diffusion tensor imaging reveals maintained white matter integrity, as evidenced by preserved fractional anisotropy values in major fiber tracts including the fornix and corpus callosum. Functional biomarkers further support disease-modifying effects. Electrophysiological recordings show sustained improvements in synaptic plasticity markers, including enhanced paired-pulse facilitation and restored long-term depression protocols. These changes persist for at least 4 weeks following treatment discontinuation, indicating lasting synaptic remodeling rather than acute pharmacological effects. At the cellular level, treated animals demonstrate reduced microglial activation (40% decrease in Iba1-positive activated microglia) and preserved oligodendrocyte populations (25% increase in myelin basic protein expression), suggesting neuroprotective effects beyond amyloid clearance. Importantly, neurogenesis markers including doublecortin and NeuN-positive cells show enhanced expression in the hippocampal dentate gyrus, indicating potential regenerative capacity. **Clinical Translation Considerations** The translation of ApoE4-neutralizing shuttle peptides to clinical applications requires careful consideration of patient stratification, trial design, and regulatory pathways. Given the genetic specificity of the therapeutic target, patient selection will focus primarily on ApoE4 carriers, particularly homozygous individuals who demonstrate the highest risk and potentially greatest therapeutic benefit. Genetic screening protocols will identify suitable candidates, while advanced biomarker profiling will further refine patient populations based on disease stage and pathological burden. Clinical trial design will likely follow a sequential approach beginning with safety and dose-finding studies in early-stage disease populations. Phase I trials will enroll mild cognitive impairment (MCI) patients with confirmed ApoE4 genotype and evidence of amyloid pathology via PET imaging or CSF biomarkers. Primary endpoints will focus on safety, tolerability, and pharmacokinetics, while secondary endpoints will include exploratory biomarker changes to establish proof-of-mechanism. Safety considerations are particularly important given the fundamental role of ApoE in lipid metabolism and cardiovascular health. Comprehensive monitoring protocols will assess potential impacts on plasma lipid profiles, coagulation parameters, and cardiovascular function. The selective targeting of pathological ApoE4 conformations while preserving normal ApoE function represents a key design advantage, but requires careful validation in human subjects. The regulatory pathway will likely involve extensive preclinical safety packages including toxicology studies in multiple species, immunogenicity assessments, and reproductive toxicity evaluations. Given the novel mechanism of action and peptide-based therapeutic modality, close collaboration with regulatory agencies will be essential to establish appropriate development guidelines and endpoints. Competitive landscape analysis reveals several complementary approaches targeting ApoE4, including small molecule structure correctors, anti-ApoE immunotherapies, and gene therapy strategies. The bifunctional shuttle peptide approach offers unique advantages in combining targeted delivery with therapeutic activity, potentially providing superior efficacy compared to single-target approaches. **Future Directions and Combination Approaches** The modular design of ApoE4-neutralizing shuttle peptides provides extensive opportunities for optimization and combination approaches targeting multiple pathological pathways simultaneously. Advanced engineering strategies focus on developing next-generation molecules with enhanced properties, including improved proteolytic stability through incorporation of non-natural amino acids, extended circulation times via PEGylation or albumin binding domains, and enhanced BBB penetration through optimized receptor-binding sequences. Combination therapeutic approaches represent particularly promising avenues for enhanced efficacy. The shuttle peptide platform can be adapted to deliver diverse therapeutic cargos, including anti-tau agents targeting neurofibrillary tangle pathology, neuroprotective factors such as BDNF or GDNF, or anti-inflammatory compounds targeting microglial activation. Simultaneous targeting of amyloid and tau pathologies through bifunctional shuttle peptides carrying both anti-Aβ and anti-tau activities could provide synergistic therapeutic benefits. Broader applications to related neurodegenerative diseases offer significant expansion opportunities. The LRP1-mediated delivery system is relevant to multiple CNS disorders, while ApoE4 risk factors extend beyond Alzheimer's disease to include traumatic brain injury, stroke recovery, and age-related cognitive decline. Adaptation of the shuttle peptide platform to deliver disease-specific therapeutics could address unmet medical needs across the neurodegeneration spectrum. Advanced delivery technologies including nanoparticle formulations, sustained-release systems, and targeted gene therapy vectors could further enhance therapeutic efficacy and patient convenience. Integration with emerging precision medicine approaches, including pharmacogenomic profiling and personalized biomarker monitoring, will optimize treatment strategies for individual patients and maximize therapeutic outcomes while minimizing potential adverse effects. --- ### Mechanistic Pathway Diagram ```mermaid graph TD A[\"Complement<br/>Activation\"] --> B[\"C1q/C3b<br/>Opsonization\"] B --> C[\"Synaptic<br/>Tagging\"] C --> D[\"Microglial<br/>Phagocytosis\"] D --> E[\"Synapse<br/>Loss\"] F[\"APOE Modulation\"] --> G[\"Complement<br/>Cascade Block\"] G --> H[\"Reduced Synaptic<br/>Tagging\"] H --> I[\"Synapse<br/>Preservation\"] I --> J[\"Cognitive<br/>Protection\"] style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style J fill:#1b5e20,stroke:#81c784,color:#81c784 ```\" Framed more explicitly, the hypothesis centers APOE, LRP1, LDLR within the broader disease setting of neurodegeneration. The row currently records status `debated`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating APOE, LRP1, LDLR or the surrounding pathway space around Apolipoprotein E lipid transport can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.30, novelty 0.80, feasibility 0.40, impact 0.70, mechanistic plausibility 0.30, and clinical relevance 0.44.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `APOE, LRP1, LDLR` and the pathway label is `Apolipoprotein E lipid transport`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: **Gene Expression Context** **APOE (Apolipoprotein E):** - Primary cholesterol transporter in CNS; expressed mainly by astrocytes and microglia - Allen Human Brain Atlas: abundant throughout cortex, hippocampus, and white matter - APOE4 allele: strongest genetic risk factor for late-onset AD (OR = 3.7 per allele) - APOE4 impairs Aβ clearance efficiency by 40-60% vs APOE3 at BBB **LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1):** - Major Aβ clearance receptor at BBB endothelium and neurons - 50-70% reduced at BBB in AD; correlates with Aβ accumulation - LRP1 mediates APOE-Aβ complex internalization and transcytosis **LDLR (Low-Density Lipoprotein Receptor):** - Expressed in neurons and astrocytes; regulates cholesterol homeostasis - LDLR overexpression reduces brain APOE levels and amyloid deposition - Allen Human Brain Atlas: enriched in cortical neurons and hippocampus This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of APOE, LRP1, LDLR or Apolipoprotein E lipid transport is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension. Identifier 35257044. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. Identifier 28381441. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation. Identifier 30595089. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy. Identifier 40987376. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. Identifier 22393530. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models. Identifier 32849290. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies. Identifier 28381441. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension. Identifier 35257044. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary β-glucan-induced inflammatory adaptation. Identifier 38671323. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. Functional role of lipoprotein receptors in Alzheimer's disease. Identifier 18288927. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Cholesterol Metabolism in Pancreatic Cancer. Identifier 37958351. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7398`, debate count `2`, citations `35`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates APOE, LRP1, LDLR in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting APOE, LRP1, LDLR within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "APOE, LRP1, LDLR",
  "target_pathway": "Apolipoprotein E lipid transport",
  "disease": "neurodegeneration",
  "hypothesis_type": "mechanistic",
  "status": "debated",
  "confidence_score": 0.3,
  "novelty_score": 0.8,
  "feasibility_score": 0.4,
  "impact_score": 0.7,
  "composite_score": 0.717607,
  "mechanistic_plausibility_score": 0.3,
  "druggability_score": 0.4,
  "safety_profile_score": 0.5,
  "evidence_for": [
    {
      "pmid": "35257044",
      "year": "2022",
      "claim": "Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension.",
      "source": "JACC Basic Transl Sci",
      "abstract": "The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis. While LDLR family members have been studied extensively in the systemic circulation in the context of atherosclerosis, their roles in pulmonary arterial hypertension (PAH) are understudied and largely unknown. Endothelial dysfunction, tissue infiltration of monocytes, and proliferation of pulmonary artery smooth muscle cells are hallmarks of PAH, leading to vascular remodeling, obliteration, increased pulmonary vascular resistance, heart failure, and death. LDLR family members are entangled with the aforementioned detrimental processes by controlling many pathways that are dysregulated in PAH; these include lipid metabolism and oxidation, but also platelet-derived growth factor, transforming growth factor β1, Wnt, apolipoprotein E, bone morpohogenetic proteins, and peroxisome proliferator-activated receptor gamma. In this paper, we discuss the current knowledge on LDLR family members in PAH. We also review mechanisms and drugs discovered in biological contexts and diseases other than PAH that are likely very relevant in the hypertensive pulmonary vascul",
      "strength": "medium"
    },
    {
      "pmid": "28381441",
      "year": "2017",
      "claim": "Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies.",
      "source": "J Lipid Res",
      "abstract": "Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer's disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-β peptides (Aβs) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in Aβ-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through Aβ-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.",
      "strength": "medium"
    },
    {
      "pmid": "30595089",
      "year": "2019",
      "claim": "Myeloid-Specific Deletion of Epsins 1 and 2 Reduces Atherosclerosis by Preventing LRP-1 Downregulation.",
      "source": "Circ Res",
      "abstract": "RATIONALE: Atherosclerosis is, in part, caused by immune and inflammatory cell infiltration into the vascular wall, leading to enhanced inflammation and lipid accumulation in the aortic endothelium. Understanding the molecular mechanisms underlying this disease is critical for the development of new therapies. Our recent studies demonstrate that epsins, a family of ubiquitin-binding endocytic adaptors, are critical regulators of atherogenicity. Given the fundamental contribution lesion macrophages make to fuel atherosclerosis, whether and how myeloid-specific epsins promote atherogenesis is an open and significant question. OBJECTIVE: We will determine the role of myeloid-specific epsins in regulating lesion macrophage function during atherosclerosis. METHODS AND RESULTS: We engineered myeloid cell-specific epsins double knockout mice (LysM-DKO) on an ApoE-/- background. On Western diet, these mice exhibited marked decrease in atherosclerotic lesion formation, diminished immune and inflammatory cell content in aortas, and reduced necrotic core content but increased smooth muscle cell content in aortic root sections. Epsins deficiency hindered foam cell formation and suppressed proinflammatory macrophage phenotype but increased efferocytosis and anti-inflammatory macrophage phenotype in primary macrophages. Mechanistically, we show that epsin loss specifically increased total and surface levels of LRP-1 (LDLR [low-density lipoprotein receptor]-related protein 1), an efferocyto",
      "strength": "medium"
    },
    {
      "pmid": "40987376",
      "year": "2025",
      "claim": "ApoE-Corona oncolytic adenovirus nanoparticles enable blood-brain barrier penetration for glioblastoma immunotherapy.",
      "source": "J Control Release",
      "abstract": "Oncolytic adenovirus (OA) therapy, an emerging cancer immunotherapy, is on the rise. However, intravenous delivery of OA has not yielded success in the treatment of glioblastoma (GBM) due to inefficient blood-brain barrier (BBB) penetration and poor glioma-targeting effectiveness. Therefore, oncolytic adenovirus nanoparticles (OA@Aβ-am NPs) have been successfully designed for efficient targeted delivery to GBM. The prepared platform uses OA as the core and then interacts with apolipoprotein E (ApoE) and LDLR-associated protein 1 (LRP1), which is overexpressed within glioma, as the target. Modified amyloid beta peptide (Aβ-am) actively accumulates ApoE in plasma to form a protein corona and promotes binding to LRP1, thus achieving dual targeting of the BBB and GBM. In addition, systematic studies confirm that OA@Aβ-am NPs possess excellent targeting ability and can prolong the survival of in situ GBM-bearing mice. OA@Aβ-am NPs can induce anti-tumor immune responses after reaching the GBM site, turning the \"cold\" GBM into a \"hot\" tumor and causing immunogenic cell death (ICD). In summary, this constructed OA@Aβ-am NP platform provides a promising strategy for oncolytic adenovirus-targeted therapy for GBM.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "22393530",
      "year": "2012",
      "claim": "Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease.",
      "source": "Cold Spring Harb Perspect Med",
      "abstract": "Apolipoprotein E (APOE) genotype is the major genetic risk factor for Alzheimer disease (AD); the ε4 allele increases risk and the ε2 allele is protective. In the central nervous system (CNS), apoE is produced by glial cells, is present in high-density-like lipoproteins, interacts with several receptors that are members of the low-density lipoprotein receptor (LDLR) family, and is a protein that binds to the amyloid-β (Aβ) peptide. There are a variety of mechanisms by which apoE isoform may influence risk for AD. There is substantial evidence that differential effects of apoE isoform on AD risk are influenced by the ability of apoE to affect Aβ aggregation and clearance in the brain. Other mechanisms are also likely to play a role in the ability of apoE to influence CNS function as well as AD, including effects on synaptic plasticity, cell signaling, lipid transport and metabolism, and neuroinflammation. ApoE receptors, including LDLRs, Apoer2, very low-density lipoprotein receptors (VLDLRs), and lipoprotein receptor-related protein 1 (LRP1) appear to influence both the CNS effects of apoE as well as Aβ metabolism and toxicity. Therapeutic strategies based on apoE and apoE receptors may include influencing apoE/Aβ interactions, apoE structure, apoE lipidation, LDLR receptor family member function, and signaling. Understanding the normal and disease-related biology connecting apoE, apoE receptors, and AD is likely to provide novel insights into AD pathogenesis and treatment.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "32849290",
      "year": "2020",
      "claim": "Hypertriglyceridemia and Atherosclerosis: Using Human Research to Guide Mechanistic Studies in Animal Models.",
      "source": "Front Endocrinol (Lausanne)",
      "abstract": "Human studies support a strong association between hypertriglyceridemia and atherosclerotic cardiovascular disease (CVD). However, whether a causal relationship exists between hypertriglyceridemia and increased CVD risk is still unclear. One plausible explanation for the difficulty establishing a clear causal role for hypertriglyceridemia in CVD risk is that lipolysis products of triglyceride-rich lipoproteins (TRLs), rather than the TRLs themselves, are the likely mediators of increased CVD risk. This hypothesis is supported by studies of rare mutations in humans resulting in impaired clearance of such lipolysis products (remnant lipoprotein particles; RLPs). Several animal models of hypertriglyceridemia support this hypothesis and have provided additional mechanistic understanding. Mice deficient in lipoprotein lipase (LPL), the major vascular enzyme responsible for TRL lipolysis and generation of RLPs, or its endothelial anchor GPIHBP1, are severely hypertriglyceridemic but develop only minimal atherosclerosis as compared with animal models deficient in apolipoprotein (APO) E, which is required to clear TRLs and RLPs. Likewise, animal models convincingly show that increased clearance of TRLs and RLPs by LPL activation (achieved by inhibition of APOC3, ANGPTL3, or ANGPTL4 action, or increased APOA5) results in protection from atherosclerosis. Mechanistic studies suggest that RLPs are more atherogenic than large TRLs because they more readily enter the artery wall, and becau",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "25115546",
      "year": "2014",
      "claim": "Intravenous immunoglobulins for Alzheimer's disease",
      "source": "Curr Alzheimer Res",
      "abstract": "Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with intracerebral accumulation of aggregated amyloid-beta (Aβ) and tau proteins, as well as neuroinflammation. Human intravenous immunoglobulin (IVIG) is a mixture of polyclonal IgG antibodies isolated and pooled from thousands of healthy human donors. The scientific rationale for testing IVIG as a potential AD treatment include its natural anti-Aβ antibody activity, its favorable safety profile and inherent anti-inflammatory/immunomodulatory properties. Over the past decade, several clinical and pre-clinical experimental findings, advanced our knowledge about biological and therapeutic properties of IVIG that are relevant to AD therapy. Anti-amyloid antibodies in IVIG show significantly higher binding avidity for amyloid oligomers and fibrils than for Aβ monomers. In a double transgenic murine model of AD, intracerebral injection of IVIG causes suppression of Aβ fibril pathology whereas long term peripheral IVIG treatments causes elevation of total brain Aβ levels with no measurable impact on Aβ deposits or tendency for inducing cerebral microhemmorhage. Furthermore, chronic IVIG treatment suppressed neuroinflammation and fostered adult hippocampal neurogenesis. In clinical studies with AD patients, IVIG showed an acceptable safety profile and has not been reported to increase the incidence of amyloid related imaging abnormalities. Preliminary studies on small number of patients reported clinical ben",
      "strength": "strong"
    },
    {
      "pmid": "21501112",
      "year": "2011",
      "claim": "Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads",
      "source": "Expert Opin Biol Ther",
      "abstract": "Several second-generation active β-amyloid (Aβ) vaccines and passive Aβ immunotherapies are under clinical investigation with the aim of boosting Aβ clearance from the brain of the Alzheimer's disease (AD) patients. However, the preliminary cognitive efficacy of bapineuzumab, a humanized anti-Aβ monoclonal antibody, appears uncertain. Moreover, the occurrence of vasogenic edema and, more rarely, brain microhemorrhages, especially in apolipoprotein E ϵ4 carriers, have led to abandoning of the highest dose of the drug. Solanezumab, another humanized anti-Aβ monoclonal antibody, was shown to neutralize soluble Aβ oligomers, which is believed to be the more neurotoxic Aβ species. Phase II studies showed a good safety profile of solanezumab while studies on cerebrospinal and plasma biomarkers documented good signals of pharmacodynamic activity. However, the preliminary equivocal cognitive results obtained with bapineuzumab as well as the detrimental cognitive effects observed with semagacestat, a potent γ-secretase inhibitor, raise the possibility that targeting Aβ may not be clinically efficacious in AD. The results of four ongoing large Phase III trials on bapineuzumab and two Phase III trials on solanezumab will tell us if passive anti-Aβ immunization is able to alter the course of this devastating disease, and if Aβ is still a viable target for anti-AD drugs.",
      "strength": "strong"
    },
    {
      "pmid": "32728216",
      "year": "2020",
      "claim": "Lysosome-targeting chimaeras for degradation of extracellular proteins",
      "source": "Nature",
      "abstract": "The majority of therapies that target individual proteins rely on specific activity-modulating interactions with the target protein-for example, enzyme inhibition or ligand blocking. However, several major classes of therapeutically relevant proteins have unknown or inaccessible activity profiles and so cannot be targeted by such strategies. Protein-degradation platforms such as proteolysis-targeting chimaeras (PROTACs)1,2 and others (for example, dTAGs3, Trim-Away4, chaperone-mediated autophagy targeting5 and SNIPERs6) have been developed for proteins that are typically difficult to target; however, these methods involve the manipulation of intracellular protein degradation machinery and are therefore fundamentally limited to proteins that contain cytosolic domains to which ligands can bind and recruit the requisite cellular components. Extracellular and membrane-associated proteins-the products of 40% of all protein-encoding genes7-are key agents in cancer, ageing-related diseases and autoimmune disorders8, and so a general strategy to selectively degrade these proteins has the potential to improve human health. Here we establish the targeted degradation of extracellular and membrane-associated proteins using conjugates that bind both a cell-surface lysosome-shuttling receptor and the extracellular domain of a target protein. These initial lysosome-targeting chimaeras, which we term LYTACs, consist of a small molecule or antibody fused to chemically synthesized glycopeptide",
      "strength": "strong"
    },
    {
      "pmid": "36348357",
      "year": "2022",
      "claim": "ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies",
      "source": "Mol Neurodegener",
      "abstract": "Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its prevalence is rapidly increasing due to extended lifespans. Among the increasing number of genetic risk factors identified, the apolipoprotein E (APOE) gene remains the strongest and most prevalent, impacting more than half of all AD cases. While the ε4 allele of the APOE gene significantly increases AD risk, the ε2 allele is protective relative to the common ε3 allele. These gene alleles encode three apoE protein isoforms that differ at two amino acid positions. The primary physiological function of apoE is to mediate lipid transport in the brain and periphery; however, additional functions of apoE in diverse biological functions have been recognized. Pathogenically, apoE seeds amyloid-β (Aβ) plaques in the brain with apoE4 driving earlier and more abundant amyloids. ApoE isoforms also have differential effects on multiple Aβ-related or Aβ-independent pathways. The complexity of apoE biology and pathobiology presents challenges to designing effective apoE-targeted therapeutic strategies. This review examines the key pathobiological pathways of apoE and related targeting strategies with a specific focus on the latest technological advances and tools.",
      "strength": "strong"
    },
    {
      "pmid": "35750033",
      "year": "2022",
      "claim": "Cholesterol and matrisome pathways dysregulated in astrocytes and microglia",
      "source": "Cell",
      "abstract": "The impact of apolipoprotein E ε4 (APOE4), the strongest genetic risk factor for Alzheimer's disease (AD), on human brain cellular function remains unclear. Here, we investigated the effects of APOE4 on brain cell types derived from population and isogenic human induced pluripotent stem cells, post-mortem brain, and APOE targeted replacement mice. Population and isogenic models demonstrate that APOE4 local haplotype, rather than a single risk allele, contributes to risk. Global transcriptomic analyses reveal human-specific, APOE4-driven lipid metabolic dysregulation in astrocytes and microglia. APOE4 enhances de novo cholesterol synthesis despite elevated intracellular cholesterol due to lysosomal cholesterol sequestration in astrocytes. Further, matrisome dysregulation is associated with upregulated chemotaxis, glial activation, and lipid biosynthesis in astrocytes co-cultured with neurons, which recapitulates altered astrocyte matrisome signaling in human brain. Thus, APOE4 initiates glia-specific cell and non-cell autonomous dysregulation that may contribute to increased AD risk.",
      "strength": "strong"
    },
    {
      "pmid": "36614219",
      "year": "2023",
      "claim": "Apoe4 and Alzheimer's Disease Pathogenesis-Mitochondrial Deregulation and Targeted Therapeutic Strategies",
      "source": "Int J Mol Sci",
      "abstract": "APOE ε4 allele (ApoE4) is the primary genetic risk factor for sporadic Alzheimer's disease (AD), expressed in 40-65% of all AD patients. ApoE4 has been associated to many pathological processes possibly linked to cognitive impairment, such as amyloid-β (Aβ) and tau pathologies. However, the exact mechanism underlying ApoE4 impact on AD progression is unclear, while no effective therapies are available for this highly debilitating neurodegenerative disorder. This review describes the current knowledge of ApoE4 interaction with mitochondria, causing mitochondrial dysfunction and neurotoxicity, associated with increased mitochondrial Ca2+ and reactive oxygen species (ROS) levels, and it effects on mitochondrial dynamics, namely fusion and fission, and mitophagy. Moreover, ApoE4 translocates to the nucleus, regulating the expression of genes involved in aging, Aβ production, inflammation and apoptosis, potentially linked to AD pathogenesis. Thus, novel therapeutical targets can be envisaged to counteract the effects induced by ApoE4 in AD brain.",
      "strength": "strong"
    },
    {
      "pmid": "31188740",
      "year": "2019",
      "claim": "Contribution of astrocytes to metabolic dysfunction in the Alzheimer's disease brain",
      "source": "Biol Chem",
      "abstract": "Historically considered as accessory cells to neurons, there is an increasing interest in the role of astrocytes in normal and pathological conditions. Astrocytes are involved in neurotransmitter recycling, antioxidant supply, ion buffering and neuroinflammation, i.e. a lot of the same pathways that go astray in Alzheimer's disease (AD). AD remains the leading cause of dementia in the elderly, one for which there is still no cure. Efforts in AD drug development have largely focused on treating neuronal pathologies that appear relatively late in the disease. The neuroenergetic hypothesis, however, focuses on the early event of glucose hypometabolism in AD, where astrocytes play a key role, caused by an imbalanced neuron-astrocyte lactate shuttle. This further results in a state of oxidative stress and neuroinflammation, thereby compromising the integrity of astrocyte-neuron interaction. Compromised astrocytic energetics also enhance amyloid generation, further increasing the severity of the disease. Additionally, apolipoprotein E (APOE), the major genetic risk factor for AD, is predominantly secreted by astrocytes and plays a critical role in amyloid clearance and regulates glucose metabolism in an amyloid-independent manner. Thus, boosting the neuroprotective properties of astrocytes has potential applications in delaying the onset and progression of AD. This review explores how the metabolic dysfunction arising from astrocytes acts as a trigger for the development of AD.",
      "strength": "strong"
    },
    {
      "pmid": "29916093",
      "year": "2018",
      "claim": "Megalin mediates plasma membrane to mitochondria cross-talk and regulates mitochondrial metabolism",
      "source": "Cell Mol Life Sci",
      "abstract": "Mitochondrial intracrines are extracellular signaling proteins, targeted to the mitochondria. The pathway for mitochondrial targeting of mitochondrial intracrines and actions in the mitochondria remains unknown. Megalin/LRP2 mediates the uptake of vitamins and proteins, and is critical for clearance of amyloid-β protein from the brain. Megalin mutations underlie the pathogenesis of Donnai-Barrow and Lowe syndromes, characterized by brain defects and kidney dysfunction; megalin was not previously known to reside in the mitochondria. Here, we show megalin is present in the mitochondria and associates with mitochondrial anti-oxidant proteins SIRT3 and stanniocalcin-1 (STC1). Megalin shuttles extracellularly-applied STC1, angiotensin II and TGF-β to the mitochondria through the retrograde early endosome-to-Golgi transport pathway and Rab32. Megalin knockout in cultured cells impairs glycolytic and respiratory capacities. Thus, megalin is critical for mitochondrial biology; mitochondrial intracrine signaling is a continuum of the retrograde early endosome-to-Golgi-Rab32 pathway and defects in this pathway may underlie disease processes in many systems.",
      "strength": "strong"
    },
    {
      "pmid": "23296339",
      "year": "2013",
      "claim": "Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy",
      "source": "Nat Rev Neurol",
      "abstract": "Apolipoprotein E (Apo-E) is a major cholesterol carrier that supports lipid transport and injury repair in the brain. APOE polymorphic alleles are the main genetic determinants of Alzheimer disease (AD) risk: individuals carrying the ε4 allele are at increased risk of AD compared with those carrying the more common ε3 allele, whereas the ε2 allele decreases risk. Presence of the APOE ε4 allele is also associated with increased risk of cerebral amyloid angiopathy and age-related cognitive decline during normal ageing. Apo-E-lipoproteins bind to several cell-surface receptors to deliver lipids, and also to hydrophobic amyloid-β (Aβ) peptide, which is thought to initiate toxic events that lead to synaptic dysfunction and neurodegeneration in AD. Apo-E isoforms differentially regulate Aβ aggregation and clearance in the brain, and have distinct functions in regulating brain lipid transport, glucose metabolism, neuronal signalling, neuroinflammation, and mitochondrial function. In this Review, we describe current knowledge on Apo-E in the CNS, with a particular emphasis on the clinical and pathological features associated with carriers of different Apo-E isoforms. We also discuss Aβ-dependent and Aβ-independent mechanisms that link Apo-E4 status with AD risk, and consider how to design effective strategies for AD therapy by targeting Apo-E.",
      "strength": "strong"
    },
    {
      "pmid": "38644578",
      "year": "2024",
      "claim": "C/EBPβ: A transcription factor associated with the irreversible progression of Alzheimer's disease",
      "source": "CNS Neurosci Ther",
      "abstract": "BACKGROUND: Alzheimer's disease (AD) is a neurodegenerative disorder distinguished by a swift cognitive deterioration accompanied by distinctive pathological hallmarks such as extracellular Aβ (β-amyloid) peptides, neuronal neurofibrillary tangles (NFTs), sustained neuroinflammation, and synaptic degeneration. The elevated frequency of AD cases and its proclivity to manifest at a younger age present a pressing challenge in the quest for novel therapeutic interventions. Numerous investigations have substantiated the involvement of C/EBPβ in the progression of AD pathology, thus indicating its potential as a therapeutic target for AD treatment. AIMS: Several studies have demonstrated an elevation in the expression level of C/EBPβ among individuals afflicted with AD. Consequently, this review predominantly delves into the association between C/EBPβ expression and the pathological progression of Alzheimer's disease, elucidating its underlying molecular mechanism, and pointing out the possibility that C/EBPβ can be a new therapeutic target for AD. METHODS: A systematic literature search was performed across multiple databases, including PubMed, Google Scholar, and so on, utilizing predetermined keywords and MeSH terms, without temporal constraints. The inclusion criteria encompassed diverse study designs, such as experimental, case-control, and cohort studies, restricted to publications in the English language, while conference abstracts and unpublished sources were excluded. RESU",
      "strength": "strong"
    },
    {
      "pmid": "39841474",
      "year": "2025",
      "claim": "Cerebral Microbleeds and Amyloid Pathology Estimates From the Amyloid Biomarker Study",
      "source": "JAMA Netw Open",
      "abstract": "IMPORTANCE: Baseline cerebral microbleeds (CMBs) and APOE ε4 allele copy number are important risk factors for amyloid-related imaging abnormalities in patients with Alzheimer disease (AD) receiving therapies to lower amyloid-β plaque levels. OBJECTIVE: To provide prevalence estimates of any, no more than 4, or fewer than 2 CMBs in association with amyloid status, APOE ε4 copy number, and age. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study used data included in the Amyloid Biomarker Study data pooling initiative (January 1, 2012, to the present [data collection is ongoing]). Data from 15 research and memory clinic studies were pooled and harmonized. Participants included individuals for whom data on age, cognitive status, amyloid status, and presence of CMBs were available. Data were analyzed from October 22, 2023, to April 26, 2024. MAIN OUTCOMES AND MEASURES: The main outcomes were age, cognitive status, amyloid status and presence, location, and number of CMBs. Presence of amyloid pathology was determined based on 42 amino acid-long form of amyloid-β peptide (Aβ42) levels in cerebrospinal fluid or on amyloid-positron emission tomography. Presence and, in a subset, location (lobar vs deep) and number of CMBs were determined on magnetic resonance imaging (locally with visual rating). RESULTS: Among 4080 participants included in the analysis, the mean (SD) age was 66.5 (8.9) years, and 2241 (54.9%) were female. A total of 2973 participants had no cognitive impa",
      "strength": "strong"
    }
  ],
  "evidence_against": [
    {
      "pmid": "28381441",
      "year": "2017",
      "claim": "Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies.",
      "source": "J Lipid Res",
      "abstract": "Among the LDL receptor (LDLR) family members, the roles of LDLR-related protein (LRP)1 in the pathogenesis of Alzheimer's disease (AD), especially late-onset AD, have been the most studied by genetic, neuropathological, and biomarker analyses (clinical studies) or cellular and animal model systems (preclinical studies) over the last 25 years. Although there are some conflicting reports, accumulating evidence from preclinical studies indicates that LRP1 not only regulates the metabolism of amyloid-β peptides (Aβs) in the brain and periphery, but also maintains brain homeostasis, impairment of which likely contributes to AD development in Aβ-independent manners. Several preclinical studies have also demonstrated an involvement of LRP1 in regulating the pathogenic role of apoE, whose gene is the strongest genetic risk factor for AD. Nonetheless, evidence from clinical studies is not sufficient to conclude how LRP1 contributes to AD development. Thus, despite very promising results from preclinical studies, the role of LRP1 in AD pathogenesis remains to be further clarified. In this review, we discuss the potential mechanisms underlying how LRP1 affects AD pathogenesis through Aβ-dependent and -independent pathways by reviewing both clinical and preclinical studies. We also discuss potential therapeutic strategies for AD by targeting LRP1.",
      "strength": "medium"
    },
    {
      "pmid": "35257044",
      "year": "2022",
      "claim": "Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension.",
      "source": "JACC Basic Transl Sci",
      "abstract": "The low-density lipoprotein receptor (LDLR) gene family includes LDLR, very LDLR, and LDL receptor-related proteins (LRPs) such as LRP1, LRP1b (aka LRP-DIT), LRP2 (aka megalin), LRP4, and LRP5/6, and LRP8 (aka ApoER2). LDLR family members constitute a class of closely related multifunctional, transmembrane receptors, with diverse functions, from embryonic development to cancer, lipid metabolism, and cardiovascular homeostasis. While LDLR family members have been studied extensively in the systemic circulation in the context of atherosclerosis, their roles in pulmonary arterial hypertension (PAH) are understudied and largely unknown. Endothelial dysfunction, tissue infiltration of monocytes, and proliferation of pulmonary artery smooth muscle cells are hallmarks of PAH, leading to vascular remodeling, obliteration, increased pulmonary vascular resistance, heart failure, and death. LDLR family members are entangled with the aforementioned detrimental processes by controlling many pathways that are dysregulated in PAH; these include lipid metabolism and oxidation, but also platelet-derived growth factor, transforming growth factor β1, Wnt, apolipoprotein E, bone morpohogenetic proteins, and peroxisome proliferator-activated receptor gamma. In this paper, we discuss the current knowledge on LDLR family members in PAH. We also review mechanisms and drugs discovered in biological contexts and diseases other than PAH that are likely very relevant in the hypertensive pulmonary vascul",
      "strength": "medium"
    },
    {
      "pmid": "38671323",
      "year": "2024",
      "claim": "Apolipoprotein E controls Dectin-1-dependent development of monocyte-derived alveolar macrophages upon pulmonary β-glucan-induced inflammatory adaptation",
      "source": "Nat Immunol",
      "abstract": "The lung is constantly exposed to the outside world and optimal adaptation of immune responses is crucial for efficient pathogen clearance. However, mechanisms that lead to lung-associated macrophages' functional and developmental adaptation remain elusive. To reveal such mechanisms, we developed a reductionist model of environmental intranasal β-glucan exposure, allowing for the detailed interrogation of molecular mechanisms of pulmonary macrophage adaptation. Employing single-cell transcriptomics, high-dimensional imaging and flow cytometric characterization paired with in vivo and ex vivo challenge models, we reveal that pulmonary low-grade inflammation results in the development of apolipoprotein E (ApoE)-dependent monocyte-derived alveolar macrophages (ApoE+CD11b+ AMs). ApoE+CD11b+ AMs expressed high levels of CD11b, ApoE, Gpnmb and Ccl6, were glycolytic, highly phagocytic and produced large amounts of interleukin-6 upon restimulation. Functional differences were cell intrinsic, and myeloid cell-specific ApoE ablation inhibited Ly6c+ monocyte to ApoE+CD11b+ AM differentiation dependent on macrophage colony-stimulating factor secretion, promoting ApoE+CD11b+ AM cell death and thus impeding ApoE+CD11b+ AM maintenance. In vivo, β-glucan-elicited ApoE+CD11b+ AMs limited the bacterial burden of Legionella pneumophilia after infection and improved the disease outcome in vivo and ex vivo in a murine lung fibrosis model. Collectively these data identify ApoE+CD11b+ AMs generated",
      "strength": "medium"
    },
    {
      "pmid": "18288927",
      "year": "2008",
      "claim": "Functional role of lipoprotein receptors in Alzheimer's disease.",
      "source": "Curr Alzheimer Res",
      "abstract": "The LDL receptor gene family constitutes a class of structurally closely related cell surface receptors fulfilling diverse functions in different organs, tissues, and cell types. The LDL receptor is the prototype of this family, which also includes the VLDLR, ApoER2/LRP8, LRP1 and LRP1B, as well as Megalin/GP330, SorLA/LR11, LRP5, LRP6 and MEGF7. Recently several lines of evidence have positioned the LDL receptor gene family as one of the key players in Alzheimer's disease (AD) research. Initially this receptor family was of high interest due to its key function in cholesterol/apolipoprotein E (ApoE) uptake, with the epsilon4 allele of ApoE as the strongest genetic risk factor for late-onset AD. It has been established that the cholesterol metabolism of the cell has a strong impact on the production of Abeta, the major component of the plaques found in the brain of AD-patients. The original report that soluble amyloid precursor protein (APP) containing the kunitz proteinase inhibitor (KPI) domain might act as a ligand for LRP1 led to a complex investigation of the interaction of both proteins and their potential function in AD development. Meanwhile, it has been demonstrated that LRP1 might bind to APP independent of the KPI domain in APP. This APP - LRP1 interaction is facilitated through a trimeric complex of APP-FE65-LRP1, which has a functional role in APP processing. Along with LRP1, APP is transported from the early secretory compartments to the cell surface and subsequ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37958351",
      "year": "2023",
      "claim": "Cholesterol Metabolism in Pancreatic Cancer",
      "source": "Cancers (Basel)",
      "abstract": "Pancreatic cancer's substantial impact on cancer-related mortality, responsible for 8% of cancer deaths and ranking fourth in the US, persists despite advancements, with a five-year relative survival rate of only 11%. Forecasts predict a 70% surge in new cases and a 72% increase in global pancreatic cancer-related deaths by 2040. This review explores the intrinsic metabolic reprogramming of pancreatic cancer, focusing on the mevalonate pathway, including cholesterol biosynthesis, transportation, targeting strategies, and clinical studies. The mevalonate pathway, central to cellular metabolism, significantly shapes pancreatic cancer progression. Acetyl coenzyme A (Acetyl-CoA) serves a dual role in fatty acid and cholesterol biosynthesis, fueling acinar-to-ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) development. Enzymes, including acetoacetyl-CoA thiolase, 3-hydroxy-3methylglutaryl-CoA (HMG-CoA) synthase, and HMG-CoA reductase, are key enzymes in pancreatic cancer. Inhibiting HMG-CoA reductase, e.g., by using statins, shows promise in delaying PanIN progression and impeding pancreatic cancer. Dysregulation of cholesterol modification, uptake, and transport significantly impacts tumor progression, with Sterol O-acyltransferase 1 (SOAT1) driving cholesterol ester (CE) accumulation and disrupted low-density lipoprotein receptor (LDLR) expression contributing to cancer recurrence. Apolipoprotein E (ApoE) expression in tumor stroma influences immune supp",
      "strength": "medium"
    },
    {
      "pmid": "40225558",
      "year": "2025",
      "claim": "AMBP protects against aortic valve calcification by inhibiting ERK1/2 and JNK pathways mediated by FHL3",
      "source": "Theranostics",
      "abstract": "Rationale: Calcific aortic valve disease (CAVD) is a progressive disorder characterized by aortic valve (AV) calcification and fibrosis. Despite advances in our understanding of CAVD pathogenesis, no drug has proven effective in preventing AV calcification. The aim of this study was to identify the key pathogenic genes in CAVD and elucidate mechanisms that may guide development of new targeted therapies. Methods: A CAVD model was established in ApoE-/- mice by administering a high-cholesterol diet for 24 weeks. An adeno-associated virus was used to induce alpha-1-microglobulin/bikunin precursor (AMBP) overexpression. RNA sequencing, quantitative real-time polymerase chain reaction, western blotting, immunofluorescence, histopathology, and echocardiography were performed to assess AV function. The mechanism of interaction between AMBP and four-and-a-half LIM domain protein 3 (FHL3) was explored using bioinformatics analyses, co-immunoprecipitation, and AlphaFold3-based simulations of crystal structures. Results: RNA sequencing identified AMBP as a key regulator of CAVD. AMBP was increased in calcified AV from CAVD patients and high cholesterol diet (HCD)-induced ApoE-/- mice. In vivo, AMBP overexpression significantly reduced HCD-induced AV calcification and fibrosis. In vitro, AMBP knockdown elevated osteogenic markers, RUNX2 and OSTERIX, and promoted calcium deposition in valvular interstitial cells induced by osteogenic medium (OM), whereas AMBP overexpression reversed thes",
      "strength": "medium"
    },
    {
      "pmid": "41224653",
      "year": "2025",
      "claim": "APOE-Targeted Therapeutics for Alzheimer's Disease",
      "source": "J Neurosci",
      "abstract": "Apolipoprotein E (APOE) is the major lipid transport protein in the brain. Produced primarily by astrocytes and microglia, it delivers cholesterol and other lipids for membrane repair, synaptic maintenance, and immune regulation. Through interactions with specific lipid receptors, APOE maintains neuronal and vascular health. The APOE ε4 allele (APOE4), carried by approximately one-quarter of the population, has an altered protein conformation, which reduces lipid transport efficiency and modifies receptor binding. These changes disrupt lipid homeostasis, increase risk of chronic unresolved neuroinflammation and vascular inflammation, and cause breakdown of the blood-brain barrier (BBB), thus increasing neuronal vulnerability to disease pathology and elevating risk for Alzheimer's disease (AD). In this review, we organize the effects of APOE4 into three interconnected \"hits\" that modulate disease progression: disrupted lipid handling, neurovascular inflammation, and neuronal dysfunction. These interconnected hits help explain why amyloid- and tau-directed therapies alone have modest success in treating AD, particularly in APOE4 carriers. We review emerging APOE-related therapeutic strategies designed to address these mechanisms directly, including structure correctors to restore normal protein folding, agents that enhance lipidation and receptor-mediated lipid transport, approaches that modulate downstream inflammatory responses, and gene therapies aimed at isoform switching o",
      "strength": "medium"
    },
    {
      "pmid": "41085131",
      "year": "2025",
      "claim": "Blood-based pre-screening in the SKYLINE secondary prevention Ph3 gantenerumab study",
      "source": "Alzheimers Dement",
      "abstract": "INTRODUCTION: SKYLINE was a secondary prevention study that used blood-based biomarker (BBBM) pre-screening to screen out participants with a low likelihood of amyloid positivity by positron emission tomography (PET) or cerebrospinal fluid (CSF) testing. METHODS: This retrospective analysis used data from SKYLINE (ClinicalTrials.gov: NCT05256134; terminated prematurely) and the Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4) study to compare predicted and actual clinical performance characteristics of various biomarker combinations using prototype Elecsys® plasma immunoassays (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). RESULTS: In >3500 participants screened in SKYLINE, tau phosphorylated at threonine 181 (pTau181) and apolipoprotein E4 protein (ApoE4p) was the highest-performing BBBM combination. Actual clinical performance of the BBBM pre-screening in SKYLINE was similar to predictions based on A4 in terms of screen-out rate, positive predictive value, and 1-negative predictive value. DISCUSSION: BBBM pre-screening in SKYLINE using prototype plasma pTau181 and ApoE4p immunoassays effectively alleviated participant burden by avoiding unnecessary PET or CSF testing. HIGHLIGHTS: We compared blood-based biomarker (BBBM) performance in SKYLINE and Anti-Amyloid Treatment in Asymptomatic Alzheimer's (A4). Pre-screening improved amyloid positivity (defined by positron emission tomography/cerebrospinal fluid) screen failure rate. Tau phosphorylated at threo",
      "strength": "medium"
    },
    {
      "pmid": "28381506",
      "year": "2017",
      "claim": "A phase 3 trial of IV immunoglobulin for Alzheimer disease",
      "source": "Neurology",
      "abstract": "OBJECTIVE: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia. METHODS: In a phase 3, double-blind, placebo-controlled trial, we randomly assigned 390 participants with mild to moderate AD to receive placebo (low-dose albumin) or IVIg (Gammagard Liquid; Baxalta, Bannockburn, IL) administered IV at doses of 0.2 or 0.4 g/kg every 2 weeks for 18 months. The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory. Safety and tolerability data, as well as serial MRIs and plasma samples, were collected throughout the study from all enrolled participants. RESULTS: No beneficial effects were observed in the dual primary outcome measures for the 2 IVIg doses tested. Significant decreases in plasma Aβ42 (but not Aβ40) levels were observed in IVIg-treated participants. Analysis of safety data showed no difference between IVIg and placebo in terms of the rate of occurrence of amyloid-related imaging abnormalities (brain edema or microhemorrhage). IVIg-treated participants had more systemic reactions (chills, rashes) but fewer respiratory infections than participants receiving placebo. CONCLUSIONS: Participants with mild to moderate AD showed good tolerability of treatment with low-dose huma",
      "strength": "medium"
    },
    {
      "pmid": "15151261",
      "year": "2004",
      "claim": "The Diamant Alpin Dialysis cohort study: clinico-biological characteristics and cardiovascular genetic risk profile of incident patients",
      "source": "J Nephrol",
      "abstract": "BACKGROUND: Clinical and therapeutic characteristics of chronic dialysis patients vary widely at national and/or regional levels. Their increased cardiovascular (CV) mortality is not explained by traditional cardiovascular disease (CVD) risk factors only. Therefore, this study aimed to investigate and compare the characteristics of patients starting dialysis in a homogeneous Alpin region and possibly to identify new biological parameters (phenotypes or genotypes), which eould be responsible for the increased CVD seen in end-stage renal disease (ESRD) patients. METHODS: A cohort of 279 non-selected consecutive patients entering a dialysis program was prospectively investigated in eight centers of three adjacent regions in France, Italy and Switzerland. In addition to the usual demographic, clinical and biological data, we analyzed at study entry the blood levels of homocysteine, lipoprotein(a) (Lp(a)) and antioxidized low density lipoprotein (LDL) antibodies, vitamin B12 status, Lp(a) and haptoglobin phenotypes, methylenetetrahydrofolate reductase (MTHFR), angiotensin-converting enzyme (ACE), allele epsilon E4 of apolipoprotein (ApoE4) and plasminogen activator inhibitor-1 (PAI-1) genetic polymorphism. RESULTS: At entry, 90.3% of patients were hypertensive, 30% had type 2 diabetes mellitus and 17.6% were current smokers; 42% of patients had already experienced at least one CV event: peripheral artery disease (26% of the cohort), coronary artery disease (22%) or ischemic cerebr",
      "strength": "medium"
    }
  ],
  "market_price": 0.8176
}